Genome-wide Association Studies Identify MiRNA-194 As a Prognostic Biomarker for Gastrointestinal Cancer by Targeting ATP6V1F, PPP1R14B, BTF3L4 and SLC7A5

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Jan 9

PMID 36620589

Authors

Pan Huang

Lingyun Xia

Qiwei Guo

Congcong Huang

Zidi Wang

Yinxuan Huang

Shanshan Qin

Weidong Leng

Dandan Li

Affiliations

Soon will be listed here.

Abstract

Background: The dysregulated genes and miRNAs in tumor progression can be used as biomarkers for tumor diagnosis and prognosis. However, the biomarkers for predicting the clinical outcome of gastrointestinal cancer (GIC) are still scarce.

Methods: Genome-wide association studies were performed to screen optimal prognostic miRNA biomarkers. RNA-seq, Ago-HITS-CLIP-seq, western blotting and qRT-PCR assays were conducted to identify target genes of miR-194. Genome-wide CRISPR-cas9 proliferation screening analysis were conducted to distinguish passenger gene and driver gene.

Results: A total of 9 prognostic miRNAs for GIC were identified by global microRNA expression analysis. Among them, miR-194 was the only one miRNA that significantly associated with overall survival, disease-specific survival and progress-free interval in both gastric, colorectal and liver cancers, indicating miR-194 was an optimal prognostic biomarker for GIC. RNA-seq analysis confirmed 18 conservative target genes of miR-194. Four of them, including ATP6V1F, PPP1R14B, BTF3L4 and SLC7A5, were directly targeted by miR-194 and required for cell proliferation. Cell proliferation assay validated that miR-194 inhibits cell proliferation by targeting ATP6V1F, PPP1R14B, BTF3L4 and SLC7A5 in GIC.

Conclusion: In summary, miR-194 is an optimal biomarker for predicting the outcome of GIC. Our finding highlights that miR-194 exerts a tumor-suppressive role in digestive system cancers by targeting ATP6V1F, PPP1R14B, BTF3L4 and SLC7A5.

Citing Articles

PPP1R14B as a potential biomarker for the identification of diagnosis and prognosis affecting tumor immunity, proliferation and migration in prostate cancer.

Bao Y, Ni Y, Zhang A, Chen J J Cancer. 2024; 15(20):6545-6564.

PMID: 39668827 PMC: 11632978. DOI: 10.7150/jca.101100.

MIR194-2HG, a miRNA host gene activated by HNF4A, inhibits gastric cancer by regulating microRNA biogenesis.

Cao H, Wang Z, Guo Q, Qin S, Li D Biol Direct. 2024; 19(1):95.

PMID: 39425187 PMC: 11487860. DOI: 10.1186/s13062-024-00549-z.

Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX.

Chang J, Yang Q, Liu X, Li W, Gao L Oncol Lett. 2024; 28(4):474.

PMID: 39161338 PMC: 11332572. DOI: 10.3892/ol.2024.14607.

lncRNA FGD5-AS1 is required for gastric cancer proliferation by inhibiting cell senescence and ROS production via stabilizing YBX1.

Qin S, Liu Y, Zhang X, Huang P, Xia L, Leng W J Exp Clin Cancer Res. 2024; 43(1):188.

PMID: 38965605 PMC: 11225384. DOI: 10.1186/s13046-024-03103-x.

IGFBP7 promotes gastric cancer by facilitating epithelial-mesenchymal transition of gastric cells.

Wang J, Wang X, Liu Z, Li S, Yin W Heliyon. 2024; 10(10):e30986.

PMID: 38778944 PMC: 11108983. DOI: 10.1016/j.heliyon.2024.e30986.

References

Fernandes R, Toubia J, Townley S, Hanson A, Dredge B, Pillman K . Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. Cell Rep. 2021; 34(1):108585. DOI: 10.1016/j.celrep.2020.108585. View

Rupaimoole R, Calin G, Lopez-Berestein G, Sood A . miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov. 2016; 6(3):235-46. PMC: 4783232. DOI: 10.1158/2159-8290.CD-15-0893. View

Laprovitera N, Grzes M, Porcellini E, Ferracin M . Cancer Site-Specific Multiple microRNA Quantification by Droplet Digital PCR. Front Oncol. 2018; 8:447. PMC: 6196277. DOI: 10.3389/fonc.2018.00447. View

Talukder A, Li X, Hu H . Position-wise binding preference is important for miRNA target site prediction. Bioinformatics. 2020; 36(12):3680-3686. PMC: 8453239. DOI: 10.1093/bioinformatics/btaa195. View

Ruvkun G . Clarifications on miRNA and cancer. Science. 2006; 311(5757):36-7. DOI: 10.1126/science.311.5757.36d. View

Reddy K . MicroRNA (miRNA) in cancer. Cancer Cell Int. 2015; 15:38. PMC: 4424445. DOI: 10.1186/s12935-015-0185-1. View

Yang X, Du W, Li H, Liu F, Khorshidi A, Rutnam Z . Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res. 2013; 41(21):9688-704. PMC: 3834805. DOI: 10.1093/nar/gkt680. View

Bao J, Zou J, Li C, Zheng G . miR-194 inhibits gastric cancer cell proliferation and tumorigenesis by targeting KDM5B. Eur Rev Med Pharmacol Sci. 2016; 20(21):4487-4493. View

Zeng Z, Zhang X, Li D, Li J, Yuan J, Gu L . Expression, Location, Clinical Implication, and Bioinformatics Analysis of RNASET2 in Gastric Adenocarcinoma. Front Oncol. 2020; 10:836. PMC: 7256199. DOI: 10.3389/fonc.2020.00836. View

10.

Blondal T, Jensby Nielsen S, Baker A, Andreasen D, Mouritzen P, Teilum M . Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2012; 59(1):S1-6. DOI: 10.1016/j.ymeth.2012.09.015. View

11.

Li D, Shen L, Zhang X, Chen Z, Huang P, Huang C . LncRNA ELF3-AS1 inhibits gastric cancer by forming a negative feedback loop with SNAI2 and regulates ELF3 mRNA stability via interacting with ILF2/ILF3 complex. J Exp Clin Cancer Res. 2022; 41(1):332. PMC: 9716751. DOI: 10.1186/s13046-022-02541-9. View

12.

Wu Q, Luo G, Yang Z, Zhu F, An Y, Shi Y . miR-17-5p promotes proliferation by targeting SOCS6 in gastric cancer cells. FEBS Lett. 2014; 588(12):2055-62. DOI: 10.1016/j.febslet.2014.04.036. View

13.

Li D, Cheng P, Wang J, Qiu X, Zhang X, Xu L . IRF6 Is Directly Regulated by ZEB1 and ELF3, and Predicts a Favorable Prognosis in Gastric Cancer. Front Oncol. 2019; 9:220. PMC: 6458252. DOI: 10.3389/fonc.2019.00220. View

14.

Bavelloni A, Ramazzotti G, Poli A, Piazzi M, Focaccia E, Blalock W . MiRNA-210: A Current Overview. Anticancer Res. 2017; 37(12):6511-6521. DOI: 10.21873/anticanres.12107. View

15.

Sun B, Fang Y, Jin D, Chen Z, Li Z, Gu X . miR-194 Inhibits the Proliferation of SW620 Colon Cancer Stem Cells Through Downregulation of SSH2 Expression. Cancer Manag Res. 2019; 11:10229-10238. PMC: 6900270. DOI: 10.2147/CMAR.S221150. View

16.

Ganju A, Khan S, Hafeez B, Behrman S, Yallapu M, Chauhan S . miRNA nanotherapeutics for cancer. Drug Discov Today. 2016; 22(2):424-432. PMC: 5309208. DOI: 10.1016/j.drudis.2016.10.014. View

17.

Wang C, Li X, Zhang L, Chen Y, Dong R, Zhang J . miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer. Int Immunopharmacol. 2021; 97:107822. DOI: 10.1016/j.intimp.2021.107822. View

18.

Mishan M, Tabari M, Parnian J, Fallahi J, Mahrooz A, Bagheri A . Functional mechanisms of miR-192 family in cancer. Genes Chromosomes Cancer. 2020; . DOI: 10.1002/gcc.22889. View

19.

Li D, She J, Hu X, Zhang M, Sun R, Qin S . The ELF3-regulated lncRNA UBE2CP3 is over-stabilized by RNA-RNA interactions and drives gastric cancer metastasis via miR-138-5p/ITGA2 axis. Oncogene. 2021; 40(35):5403-5415. PMC: 8413130. DOI: 10.1038/s41388-021-01948-6. View

20.

Wang J, Zhang M, Hu X, She J, Sun R, Qin S . miRNA-194 predicts favorable prognosis in gastric cancer and inhibits gastric cancer cell growth by targeting CCND1. FEBS Open Bio. 2021; 11(7):1814-1826. PMC: 8255842. DOI: 10.1002/2211-5463.13125. View